111 related articles for article (PubMed ID: 3384616)
1. Detection of tumors with 19F magnetic resonance imaging.
Ratner AV; Muller HH; Bradley-Simpson B; Johnson DE; Hurd RE; Sotak C; Young SW
Invest Radiol; 1988 May; 23(5):361-4. PubMed ID: 3384616
[TBL] [Abstract][Full Text] [Related]
2. Use of fluorine-19 nuclear magnetic resonance spectroscopy and hydralazine for measuring dynamic changes in blood perfusion volume in tumors in mice.
Thomas C; Counsell C; Wood P; Adams GE
J Natl Cancer Inst; 1992 Feb; 84(3):174-80. PubMed ID: 1542128
[TBL] [Abstract][Full Text] [Related]
3. 19F magnetic resonance imaging of the reticuloendothelial system.
Ratner AV; Hurd R; Muller HH; Bradley-Simpson B; Pitts W; Shibata D; Sotak C; Young SW
Magn Reson Med; 1987 Dec; 5(6):548-54. PubMed ID: 3437815
[TBL] [Abstract][Full Text] [Related]
4. Rapid 19F magnetic resonance imaging of perfluorooctyl bromide in vivo.
Freeman DM; Muller HH; Hurd RE; Young SW
Magn Reson Imaging; 1988; 6(1):61-4. PubMed ID: 3352482
[No Abstract] [Full Text] [Related]
5. Perfluoroctylbromide: a liver/spleen-specific and tumor-imaging ultrasound contrast material.
Mattrey RF; Scheible FW; Gosink BB; Leopold GR; Long DM; Higgins CB
Radiology; 1982 Dec; 145(3):759-62. PubMed ID: 7146409
[TBL] [Abstract][Full Text] [Related]
6. Perfluoroctylbromide: a reticuloendothelial-specific and tumor-imaging agent for computed tomography.
Mattrey RF; Long DM; Multer F; Mitten R; Higgins CB
Radiology; 1982 Dec; 145(3):755-8. PubMed ID: 7146408
[TBL] [Abstract][Full Text] [Related]
7. A new perfluorocarbon for use in fluorine-19 magnetic resonance imaging and spectroscopy.
Sotak CH; Hees PS; Huang HN; Hung MH; Krespan CG; Raynolds S
Magn Reson Med; 1993 Feb; 29(2):188-95. PubMed ID: 8429782
[TBL] [Abstract][Full Text] [Related]
8. [19F-MR imaging of transplanted tumor: perfluorochemicals as a fluorine tumor imaging agent].
Itoh YH; Kandori Y; Takahashi M; Fritz-Zieroth B; Miyata N
Nihon Igaku Hoshasen Gakkai Zasshi; 1995 Apr; 55(5):345-7. PubMed ID: 7784157
[TBL] [Abstract][Full Text] [Related]
9. Tumor imaging with anti-CEA antibody labeled 19F emulsion.
Shimizu M; Kobayashi T; Morimoto H; Matsuura N; Shimano T; Nomura N; Itoh S; Yamazaki M; Iriguchi N; Yamamoto T
Magn Reson Med; 1987 Sep; 5(3):290-5. PubMed ID: 3431398
[TBL] [Abstract][Full Text] [Related]
10. Perfluorocarbon distribution to liver, lung and spleen of emulsions of perfluorotributylamine (FTBA) in pigs and rats and perfluorooctyl bromide (PFOB) in rats and dogs by 19F NMR spectroscopy.
McGoron AJ; Pratt R; Zhang J; Shiferaw Y; Thomas S; Millard R
Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(4):1243-50. PubMed ID: 7849929
[TBL] [Abstract][Full Text] [Related]
11. Perfluorocarbon imaging in vivo: a 19F MRI study in tumor-bearing mice.
Mason RP; Antich PP; Babcock EE; Gerberich JL; Nunnally RL
Magn Reson Imaging; 1989; 7(5):475-85. PubMed ID: 2607898
[TBL] [Abstract][Full Text] [Related]
12. High sensitivity 19F MRI of a perfluorooctyl bromide emulsion: application to a dynamic biodistribution study and oxygen tension mapping in the mouse liver and spleen.
Giraudeau C; Djemaï B; Ghaly MA; Boumezbeur F; Mériaux S; Robert P; Port M; Robic C; Le Bihan D; Lethimonnier F; Valette J
NMR Biomed; 2012 Apr; 25(4):654-60. PubMed ID: 21953998
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia.
Aboagye EO; Maxwell RJ; Kelson AB; Tracy M; Lewis AD; Graham MA; Horsman MR; Griffiths JR; Workman P
Cancer Res; 1997 Aug; 57(15):3314-8. PubMed ID: 9242466
[TBL] [Abstract][Full Text] [Related]
14. Measurement of differences in pO2 in response to perfluorocarbon/carbogen in FSa and NFSa murine fibrosarcomas with low-frequency electron paramagnetic resonance oximetry.
Halpern HJ; Yu C; Peric M; Barth ED; Karczmar GS; River JN; Grdina DJ; Teicher BA
Radiat Res; 1996 May; 145(5):610-8. PubMed ID: 8619027
[TBL] [Abstract][Full Text] [Related]
15. 19F molecular MR imaging for detection of brain tumor angiogenesis: in vivo validation using targeted PFOB nanoparticles.
Giraudeau C; Geffroy F; Mériaux S; Boumezbeur F; Robert P; Port M; Robic C; Le Bihan D; Lethimonnier F; Valette J
Angiogenesis; 2013 Jan; 16(1):171-9. PubMed ID: 23053783
[TBL] [Abstract][Full Text] [Related]
16. Correction of chemical-shift artifacts in 19F imaging of PFOB: a robust signed magnitude method.
Lee HK; Nalcioglu O; Buxton RB
Magn Reson Med; 1992 Feb; 23(2):254-63. PubMed ID: 1549040
[TBL] [Abstract][Full Text] [Related]
17. Phagocytosis of a PFOB-Nanoemulsion for
Nienhaus F; Colley D; Jahn A; Pfeiler S; Flocke V; Temme S; Kelm M; Gerdes N; Flögel U; Bönner F
Molecules; 2019 May; 24(11):. PubMed ID: 31151162
[TBL] [Abstract][Full Text] [Related]
18. Effect of emulsion concentration on biodistribution of perflubron in tumor-bearing mice.
Long DM; Witt BL; Escobar JA; Long RA
Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):907-10. PubMed ID: 1391531
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance spectroscopy studies on experimental murine and human tumors: comparison of changes in phosphorus metabolism with induced changes in vascular volume.
Adams GE; Bremner JC; Counsell CJ; Stratford IJ; Thomas C; Wood PJ
Int J Radiat Oncol Biol Phys; 1992; 22(3):467-71. PubMed ID: 1735680
[TBL] [Abstract][Full Text] [Related]
20. Probing different perfluorocarbons for in vivo inflammation imaging by 19F MRI: image reconstruction, biological half-lives and sensitivity.
Jacoby C; Temme S; Mayenfels F; Benoit N; Krafft MP; Schubert R; Schrader J; Flögel U
NMR Biomed; 2014 Mar; 27(3):261-71. PubMed ID: 24353148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
